25 results about "Myocarditis" patented technology

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

This invention discloses a myocarditis treatment prediction system integrating Transformer and causal reinforcement learning, comprising a data preprocessing module, a temporal encoding module, a causal decision-making module, and an interpretation regularization module. The data preprocessing module transforms multimodal clinical data into equally spaced state representation sequences; the temporal encoding module extracts global temporal dependencies through the multi-head self-attention mechanism of a Transformer encoder, outputting an abstract state vector; the causal decision-making module uses the abstract state vector as input to construct a Markov decision process, employs offline strategies to evaluate and estimate the expected clinical benefits of different intervention timings, and outputs individualized intervention recommendations and confidence levels through policy gradient optimization. This invention can capture the dynamic evolution of myocarditis disease under limited case conditions, assess the causal effects of different intervention strategies without real clinical trials, and provides a transparent and interpretable decision-making process, effectively assisting clinicians in identifying the optimal timing for immunosuppressive therapy.

The invention discloses a polypeptide for inducing immune myocarditis and application of the polypeptide. The polypeptide comprises an amino acid sequence as shown in at least one of SEQ ID NO. 1 to SEQ ID NO. 39. The polypeptide has obvious immunogenicity and inflammatory potential, and can be used as a stable and repeatable immune myocarditis induction system.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

The novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are NLRP3 inhibitors and may be useful in the treatment, prevention, management, improvement, control, and suppression of NLRP3-mediated diseases. The compounds of the present invention may be useful in the treatment, prevention, or management of NLRP3-mediated diseases, disorders, and conditions such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, Lewy body dementia (LBD), and traumatic brain injury. (I)

The present invention provides biomarkers for predicting immune-related myasthenia gravis, myocarditis, and myositis. The key locus HLA-DQB1 * 03: 03 is obtained through HLA typing, and the method has a good prediction value on whether tumor patients subjected to ICI treatment suffer from irMG and / or myositis and myocarditis or not. The invention provides a screening tool which can identify a potential high-risk irAE patient before ICI treatment, and provides inspiration for preventive treatment development of irMG susceptible people.

This invention relates to the field of biodetection technology, specifically to a multimodal miRNA detection array based on Mn-CeO2@CDs nanozymes and Cas12a sensing, its preparation method, and its applications. The recognition and signal amplification probe composition based on Mn-CeO2@CDs nanozymes and Cas12a includes: a solid substrate, the DNA Y-shaped structure described in the first aspect, the composite nanozyme, and a CRISPR / Cas12a system. This invention combines DNA nanotechnology, Cas12a enzyme digestion technology, and nanozymes as signal output mediators, achieving highly specific and sensitive multimodal detection of myocarditis biomarkers (miRNAs) in fluorescence, UV-visualization, and electrochemical modes.

Disclosed herein are methods and materials for treating myocarditis with gene therapy. In some cases, disclosed herein are methods and material for treating myocarditis in a subject in need thereof comprising administering to the subject an effective amount of a vector comprising a nucleic acid sequence encoding a connexin 43 polypeptide operably linked to a promoter active in cardiac muscle tissue. Also disclosed herein are methods of treating myocarditis by administering to a subject an agent that increases the level of a connexin 43 encoding nucleic acid molecule or connexin 43 polypeptide.

The invention provides antibody functionalized Au and Raman signal molecule and Au nanoparticles, a sandwich structure formed by combining magnetic beads and nanoparticles and application of the sandwich structure, and belongs to the technical field of myocarditis related index detection. A Raman signal molecule is introduced into the surface of a gold nanoparticle, a gold shell layer is deposited, the surface of the gold shell layer is modified with an antibody, and the antibody functionalized Au and Raman signal molecule and Au nanoparticle is constructed. According to the invention, the silver-coated gold nanoparticles are prepared, silver on the outer layers of the silver-coated gold nanoparticles can be etched while the silver-coated gold nanoparticles and a second part of HAuCl4 are subjected to reduction reaction to coat a gold shell layer, and a nano cavity with extremely strong hot spots is formed between an inner-layer nano gold core and an outer-layer gold shell, so that amplification can be realized, and repeatable Raman signal reading can be realized; and accurate detection is promoted. The sandwich structure formed by further combining the magnetic beads and the nanoparticles can accurately and quickly realize Raman spectrum identification of five positive and negative samples of myocarditis.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

An object of the present invention is to provide a novel composition for treating myocarditis and / or a novel composition for preventing the myocarditis. A composition containing an inhibitor of VLA-4 for preventing or treating the myocarditis is provided.

The invention provides a novel ferroptosis inhibitor as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis medicines. The invention synthesizes a compound shown in the formula I and having a good inhibition effect on ferroptosis, and the compound can be used for preparing a ferroptosis inhibitor. The compound can also be used for preparing medicines for treating diseases such as ischemia-reperfusion injury, drug-induced liver injury, acute kidney injury, renal failure, hepatic pulmonary fibrosis, neurodegenerative diseases, cerebral apoplexy, myocarditis, myocardial infarction, heart failure, arthritis, chronic atrophic gastritis and the like related to ferroptosis, and has a wide market prospect.

The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.

The invention relates to the technical field of biological medicines, in particular to application of an insulin-like growth factor 2 receptor IGF2R inhibitor in preparation of a medicine for preventing and / or treating fulminant myocarditis. The result of the embodiment of the invention shows that the IGF2R expression of the heart tissue is abnormally increased in the state of fulminating myocarditis, and is more obvious in myocardial cells. Expression and / or related biological functions of IGF2R are / is inhibited in a myocardial cell specific mode, the survival outcome of an animal model with fulminating myocarditis can be improved, the systolic and diastolic functions of the heart can be improved, myocardial damage markers are reduced, myocardial tissue inflammatory response is relieved, and the inflammatory factor level is reduced. The application disclosed by the invention is suitable for fulminating myocarditis types including but not limited to viral fulminating myocarditis, and a new intervention strategy and a potential drug target can be provided for the diseases.

The invention discloses a method and a system for predicting myocarditis based on protein expression. The method comprises the following steps: collecting a blood sample of a subject, quantitatively detecting expression levels of cardiac muscle specificity and inflammation related proteins such as cTnI, H-FABP and SAA at the same time by adopting an enzyme-linked immunosorbent assay, carrying out standardized correction by utilizing an internal reference protein, and inputting corrected data into a multivariable logistic regression model based on large-scale population data training. And calculating a comprehensive risk score. The system comprises a sample pretreatment module, a multiple protein quantitative detection module, an analysis module and a clinical report generation module, and supports automatic detection, dynamic weight adjustment and trend analysis. Through multi-marker combined analysis and modeling integration, the specificity and early warning capability of myocarditis diagnosis are remarkably improved, risk stratification and personalized treatment assistance are realized, and the limitation that a traditional method depends on a single marker and subjective experience is overcome.

The invention relates to the field of biomedicine, and discloses a prediction model for myocarditis related to a hormone-resistant immune checkpoint inhibitor. The invention discloses application of a marker combination CXCL9, MMP1 and TRANCE in construction of a myocarditis prediction model related to a hormone-resistant immune checkpoint inhibitor, and constructs the myocarditis prediction model related to the hormone-resistant immune checkpoint inhibitor, the model has high prediction efficiency (AUC = 0.91), and a reliable prediction model is provided for early recognition of srICIAM patients.

Provided in the present application are a phenylacrylamide compound, and a preparation method therefor and the use thereof. The phenylacrylamide compound has a structure represented by formula I. The phenylacrylamide compound provided in the present application can exhibit good binding to a plurality of target proteins, particularly exhibiting a good inhibitory activity against ACAT1 and 3-KAT targets, and has good bioavailability. The compound can be used in the preparation of a drug for preventing or treating tumors, cancer pain, radiotherapy- and chemotherapy-induced injuries, autoimmune diseases, infections, drug-induced myocarditis, cytokine storms, ischemic heart disease, inflammatory diseases and neurodegenerative diseases, or for anti-aging.

The rapid development of tumor molecular targeted drugs and immunotherapy promotes the progress of tumor treatment field, but the treatment means of related adverse reactions is very single, the application discloses a kind of traditional Chinese medicine composition and preparation method for preventing and treating new generation of tumor targeted and immunotherapy related adverse reactions.The composition includes the following mass parts of traditional Chinese medicinal materials: 3-20 parts of radix astragali, 3-18 parts of radix rehmanniae, 3-15 parts of radix lithospermi, 3-20 parts of old snake tongue grass, 3-20 parts of white milk vetch, 3-18 parts of old heron grass, 3-12 parts of gallnut, 3-20 parts of fried elaterium, 3-10 parts of raw licorice.The traditional Chinese medicine composition has the effects of nourishing yin and benefiting qi, promoting blood circulation to expel wind, detoxifying and removing turbidity, and is good for preventing and treating skin rash, gastrointestinal inflammation and diarrhea, hypothyroidism, proteinuria, hypertension, pneumonia, myocarditis and the like.The preparation method is decoction, granules, pills and capsule preparations.The application is simple, economical and effective, has no toxic side effects, and is helpful to prolong the tolerance period of targeted and immunotherapy and improve the survival quality of patients.

This application discloses the use of naphthalene ring-based low-molecular-weight compounds. This application is the first to discover that compounds represented by general formula I have excellent therapeutic effects against various intractable diseases, including reproductive system diseases, autoimmune diseases, skin diseases, eye diseases, muscle or bone degenerative diseases, neurological diseases, anemia, adrenal diseases, chronic gastritis, myocarditis, periodontitis, hypothyroidism, alopecia, liver damage, tinnitus, and chronic obstructive pulmonary disease. Therefore, this has extremely great application value in the prevention and treatment of the aforementioned diseases.

This invention discloses a biomarker and its application in the diagnosis of fulminant myocarditis. This invention is the first to discover that the expression levels of chemokines CXCL2 and CXCL3 in the blood of patients with fulminant myocarditis are significantly higher than those in normal individuals, and the difference is statistically significant. By detecting the expression levels of chemokines CXCL2 and CXCL3 in human blood, fulminant myocarditis can be effectively detected. Verification has shown that CXCL2 and CXCL3, as biomarkers for diagnosing fulminant myocarditis, have high accuracy, specificity, and sensitivity. Therefore, they can be used as detection targets in the diagnosis of patients with fulminant myocarditis, demonstrating good application value.

The invention discloses a targeted mitochondria lactic acid nano-drug compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano-drug compound comprises a lipidosome delivery carrier, a lactic acid transporter MCT1 inhibitor AZD3965 loaded in lipidosome, and mitochondrial targeting cationic group triphenyl phosphate TPP and heart targeting peptide CTP which are coupled to the surface of the lipidosome. The nano-drug provided by the invention can effectively and quickly deliver an effective drug lactic acid transporter MCT1 inhibitor AZD3965 to mitochondria in the heart, effectively reduce lactic acid entering the mitochondria, reduce abundance of heart mitochondria protein lactylation modification, improve the cardiac function index of a myocarditis group, relieve the degree of cardiac fibrosis, and improve the cardiac function index of a myocardial infarction group. The myocardial mitochondrial injury is improved, the inflammatory factor level is reduced, and the effect of improving myocarditis is further achieved. And moreover, the nano-drug shows good in-vivo safety and biocompatibility in vivo. The invention provides a new scheme for treating myocarditis.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

The invention provides application of ailanone in inhibiting HK2 regulation glycolysis and treating metabolic inflammation cross diseases, and belongs to the technical field of biological medicines. The invention reveals for the first time that ailanone (AIL) can significantly alleviate sepsis-related myocardial damage by targeting HK2, and has good biological safety. After the AIL is used for treating an animal model, the heart blood pumping function can be remarkably recovered; the level of myocardial injury markers is reduced; the tissue damage is obviously relieved. Meanwhile, a staining experiment proves that the AIL can effectively reduce the LPS-induced myocardial cell apoptosis rate and obviously reduce the Ly6G level, and proves that the AIL can improve cell apoptosis and immune injury. The ailanthus altissima ketone inhibits HK2 to regulate glycolysis, breaks the metabolic abnormality loop in the SCM pathogenesis process, and is suitable for treatment of multiple metabolic inflammation cross diseases such as sepsis, myocarditis, inflammatory cardiovascular diseases and the like.